A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study ID
- NCT05614063
- Phase
- PHASE3
- Status
- Completed
Conditions
- Focal Onset Seizures
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- XEN1101 — DRUGXEN1101 Capsules
- Placebo — DRUGPlacebo Capsules
Study Details
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Key Dates
- Start date
- Nov 18, 2022
- Status verified
- May 2026
- Primary completion
- Jan 12, 2026
- Completion
- Feb 3, 2026
Study Design
- Enrollment
- 380 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: XEN1101 25 mg/dayXEN1101 25 mg/day
- Experimental: XEN1101 15 mg/dayXEN1101 15 mg/day
- Placebo Comparator: PlaceboPlacebo
Primary Outcome Measure
Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo. [ Time Frame: From baseline through to the double blind period (week 12) ]
Locations (56)
Find similar trials in Mobile, AL
By research site
Strada Patient Care Center· Mobile, ALXenoscience· Phoenix, AZUniversity of Arizona, Health Sciences Center· Tucson, AZClinical Trials, Inc· Little Rock, ARBrain Science Research Institute· Los Angeles, CAUniversity of California, David Clinical & Translational Science Center Clinical Research (CCRC)· Sacramento, CA
Related Studies
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)PHASE3 · Recruiting · Xenon Pharmaceuticals Inc. · Little Rock, Arkansas
- RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresPHASE2 · Recruiting · Supernus Pharmaceuticals, Inc. · Port Charlotte, Florida
- SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresPHASE2 · Recruiting · Supernus Pharmaceuticals, Inc. · Port Charlotte, Florida